AI assistant
RIGEL PHARMACEUTICALS INC — Director's Dealing 2025
May 28, 2025
32801_dirs_2025-05-28_3ce27bcd-1fbc-4685-80ca-70768cd6e592.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2025-05-23
Reporting Person: HANNAH ALISON L. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-23 | Common Stock | A | 2500 | — | Acquired | 10625 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-23 | Stock Option (Right to Buy) | $18.95 | A | 3000 | Acquired | 2035-05-23 | Common Stock (3000) | Direct |
Footnotes
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
F2: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F3: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.